| INTRODUCTION
Antiphospholipid antibody syndrome (APS) is characterized by a predisposition to arterial and venous thromboebolism in the presence of antiphospholipid antibodies (APLA). APS afflicts people of all ages, including children and adolescents, and is characterized by up to a 40-fold increased risk of arterial and venous thromboembolism in the setting of persistent APLA. 1 APS is an autoimmune disorder with the pathological formation of antibodies against various host antigens. In addition to the thromboembolic events, APS has a significant effect on maternal/fetal health, as women with APLA are at a higher risk for miscarriages and thrombotic events during pregnancy. 2 The most common thrombotic events associated with APS are ischemic stroke and deep venous thromboembolism. Additionally, the diagnosis of APS may commit a patient to indefinite anticoagulation, decreasing their quality of life and exposing them to risks of hemorrhage. 3, 4 The underlying mechanism that predisposes these patients to thrombosis
is not well understood but is thought to be the multifactorial activation of various components of the blood and vasculature. 1, 5 Many of the pathophysiological mechanisms in APS have been attributed to anti-β2GPI IgG antibodies. 6 Clinically, patients with anti-β2GPI antibodies are at a higher risk for thrombotic events as compared to other types of APLA. 7, 8 Anti-β2GPI antibodies activate leukocytes, platelets, endothelial cells and, more recently, have been shown to augment thrombus formation in vivo. 6, [9] [10] [11] One important consequence of endothelial activation is the release of the hemostatic protein von Willebrand factor (VWF). We therefore sought to investigate the effects of anti-β2GPI antibodies on the regulation of VWF in APS.
VWF has two main functions in hemostasis: (i) to bind to exposed subendothelial collagen at sites of vessel injury and capture platelets during primary hemostasis, and (ii) to stabilize coagulation factor VIII. In addition, in certain pathological states, endothelial-released VWF remains attached to the endothelial surface, providing a surface on which platelets can accumulate.
While deficiency of VWF characterizes von Willebrand disease, elevations of VWF have also been implicated in thrombotic disorders, specifically cardiovascular disease, myocardial infarction, and arterial ischemic stroke. [12] [13] [14] [15] The unique predisposition of APS to arterial stroke suggests that VWF, which has significant importance in arterial, platelet-rich thrombi, may play a role in the predisposition to thromboembolism seen in APS. Several reports have demonstrated an increase in cell surface VWF on endothelial cells treated with APL-Abs and higher levels of active VWF in the serum of patients with anti-β2GPI antibodies. [16] [17] [18] [19] VWF is modulated by ADAMTS13 (a-disintegrin-andmetalloproteinase-with-a-thrombospondin-type-motif, member 13), which cleaves highly hemostatic ultra large VWF (ULVWF) complexes into smaller units. Deficiency of ADAMTS13, either congenital (Upshaw-Schulman syndrome) or acquired (usually due to acquired autoantibodies), leads to thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis in the clinical syndrome of thrombotic thrombocytopenic pupura. 20 In this syndrome, patients are at high risk of thrombosis due to the presence of circulating ultra large molecular weight VWF that is highly hemostatically active.
Previously, there have been varied reports of ADAMTS13 levels, activity, and the presence of anti-ADAMTS13 antibodies in APS. 16, 17, 21 More recently, reduced ADAMTS13 activity was shown to correlate with thrombotic risk in a large cohort of patients with APS. 22 We therefore sought to investigate the role of VWF and ADAMTS13 in thrombosis associated with APS. In this study, we specifically investigated the role of anti-β2GPI in VWF release from endothelial cells and the role of anti-β2GPI in the modulation of ADAMTS13 activity.
| MATERIALS AND METHODS

| Materials
Control human and rabbit IgG were purchased from Jackson 
| Patient samples
Patients were enrolled in a IRB-approved study (University of Colorado COMIRB 09-0816) and blood was collected into sodium citrate (BD Vacutainer, San Jose, CA, USA). Platelet-poor plasma was isolated via centrifugation of whole blood, twice, at 2500 × g for 30 minutes at 4C prior to cryopreservation at −80°C. Four patient samples were used in this study (APS155, APS698, APS25, APS203).
Patients were confirmed to have the clinical diagnosis of APS per the updated Sapporo/Sydney criteria (which requires a history of a thromboembolic event). 23 See Table 1 for further descriptive information regarding clinical characteristics and APLA levels. Of note, patients were chosen to represent both individuals with and without high levels of anti-β2GPI to represent the clinical heterogeneity seen in APS.
| Anti-β2GPI antibody isolation
Anti-β2GPI antibodies from subjects and from a β2GPI-immunized rabbit were affinity purified using an Affigel HZ column to which purified human β2GPI was coupled (Bio-Rad Laboratories, Hercules, CA, USA), as previously described. 
| Endothelial cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Basel, Switzerland). Endothelial cells were maintained using EBM2-MV (Lonza, Basel, Switzerland). All experiments were performed using cells of passage 6 or lower.
| VWF release assays
Confluent HUVECs in 96-well microplates were incubated in serum free-media for a minimum of two hours before incubation for one hour in EBM2 serum-free media containing patient-derived anti-β2GPI antibodies (600 nmol L −1 ) and ± β2GPI (Haematologic Technologies Inc, Essex Junction, VT, USA). After incubation, conditioned serum-free medium was removed and frozen at −80°C. VWF antigen release was measured by ELISA as described previously. 28 In brief, monoclonal antibodies (Blood Center of Wisconsin) were coated on a 96-well plate and after blocking, conditioned medium is incubated for one hour. Total VWF bound is detected using an anti-VWF polyclonal antibody and an HRP-linked secondary antibody and optical densities (OD) are compared to a standard curve of pooled normal plasma (PNP) where the VWF concentration is assumed to be 100 mU/mL. 
| VWF propeptide assays
Catastrophic antiphospholipid syndrome (sentinel episode three years prior to lab draw) Non-acute state at time of draw Medications warfarin
ImmunoResearch Laboratories, West Grove, PA, USA) and developed using PNPP. OD results are compared to a standard curve of PNP where the VWF propetide concentration is assumed to be 100 mU/mL. 
| Weibel-Palade body assay
| ADAMTS13 activity assays
ADAMTS13 activity in patient plasma was measured as the enzyme's ability to cleave a biotinlyated VWF A2 peptide substrate conjugated to HRP. 30 Platelet numbers before and after ADAMTS13 perfusion were compared. The difference served as a proxy for ADAMTS13 activity.
| VWF string cleavage model
| Multimer analysis
The equivalent of 1 mU VWF (determined via ELISA) from patient plasma was run in each lane of a 2% HGT agarose (Lonza, Rockland, ME, USA) resolving gel containing 1% sodium dodecyl sulfate (SDS) for 16 hours at 40V followed by electroblot transfer for one hour at 100V to an Immobilon-P (Millipore, Billerica, 
| Statistical analysis
All experiments were performed a minimum of three times and statistical analysis was conducted via 1-one ANOVA or paired t-test;
significance was defined by a p-value <.05. Data was analyzed using
GraphPad Prism version 7.00 for Mac (GraphPad Software, La Jolla, CA, USA).
| RESULTS
| VWF and VWFpp secretion from endothelial cells in response to anti-β2GPI antibodies
In previous reports, APS serum or APS IgG fractions have been shown to increase cell surface VWF from endothelial cells. [31] [32] [33] To determine the amounts of VWF released by endothelial cells into the cellular supernatant, endothelial cells were exposed to four patient-derived anti-β2GPI antibodies (APS25, APS203, APS155, and APS698) and the conditioned media were assayed by ELISA.
Exposure to APS25 and APS203 as well as to a polyclonal rabbit anti-β2GPI antibody was associated with a statistically significant increase in VWF release when compared to control human IgG and control rabbit IgG ( Figure 1A ). Interestingly, there was a wide variation in the amount of VWF released among the patientderived anti-β2GPI antibodies. While APS25 and APS203 showed significant increases, APS155 and APS698 showed increased VWF release but the differences did not reach statistical significance when compared to control IgG ( Figure 1A) . Similarly, to confirm the acute release of VWF we also assayed VWF propeptide (VWFpp) which is expected to be released in equimolar amounts with mature VWF in medium conditioned by HUVEC exposed to the same patient-derived anti-β2GPI antibodies ( Figure 1B) . In this assay, APS25 induced a statistically significant increase in VWF release while the three other Anti-β2GPI antibodies induced increased release but they did not reach significance. Since β2GPI
has been proposed as a hemostatic modulator and is thought to bind to cells and act as a "targeting" molecule for anti-β2GPI antibodies, we performed the same experiments in the presence of β2GPI. 24, 26, 34 The results were similar to those without β2GPI (Supplemental Figure 1 ) although they did not reach statistical significance.
F I G U R E 1 Anti-β2GPI antibodies increase VWF and VWFpp release from endothelial cells. HUVECs were plated in a 96-well plate and cultured until reaching 100% confluence. Cells were then washed in serum-free EBM2 and incubated for 2 hours in serum-free EBM2 prior to incubation in EBM2 plus the control or Anti-β2GPI antibodies (600nM). Conditioned media is collected and frozen at -80ºC for future use. 
| Anti-β2GPI antibodies cause dysfunction of ADAMTS13
We next investigated the effects of patient-derived anti-β2GPI antibodies on ADAMTS13 activity. Loss of ADAMTS13 activity, as measured in a VWF-platelet string assay has been reported in TTP. 19 We therefore tested the ability of ADAMTS13 to cleave VWF-platelet strings in the presence of control or patient-derived anti-β2GPI antibodies. The anti-β2GPI antibody APS155 significantly reduced ADAMTS13 activity as compared to control IgG. Differences attributable to APS203
and APS698 did not show statistical significance compared to control
IgG but APS203 showed a trend towards a decrease in ADAMTS13 activity ( Figure 3) . These results were consistent with a FRET-assay of ADAMTS13 activity in plasma isolated from APS155 and APS203 which demonstrated decreased ADAMTS13 activity when compared to control (Table 2) 
| DISCUSSION
In this report, we sought to further investigate the role of VWF in the prothrombotic nature of APS. We hypothesized that anti-β2GPI antibodies would stimulate VWF release from endothelial cells and tested this hypothesis by assaying VWF release, both into the supernatant as well as cellular-based VWF (VWF platelet strings). We also hypothesized that anti-β2GPI antibodies would have an effect on ADAMTS13, the primary modulator of VWF function in vivo. We have demonstrated that some, but not all anti-β2GPI antibodies induced the release of VWF and that this release is not associated with VWF-platelet string formation. We have also demonstrated that the APS155 anti-β2GPI antibody can induce dysfunction of ADAMTS13 represented by decreased cleavage of VWF strings. This finding was similar to decreased ADAMTS13 activity in a FRET-based assay on APS155 plasma and this effect may be reflected in VWF multimer patterns.
In the VWF release assay, APS25 and APS203 induced significant increases in VWF release as compared to control human IgG.
A similar finding was seen for a rabbit polyclonal anti-β2GPI antibody. APS698 and APS155 demonstrated non-statistically significant increases in VWF release. Similar findings were also seen in our VWFpp assay which largely confirmed the "acute" release of VWF from endothelial cells and minimized the concern of contaminating VWF from cellular media or other sources. Our Weibel-Palade body findings suggest that anti-β2GPI, in addition to inducing release of VWF may also affect VWF expression and packaging as represented by increased Weibel-Palade body formation. The increase in VWF observed in our assay may mirror the in vivo effects seen in some of APS patients as they tend to have elevated levels of total and active VWF. 15, 20 Elevations of VWF in turn can lead to thrombotic events. [11] [12] [13] [14] Interestingly, the variation of VWF release induced by anti-β2GPI antibodies from different patients suggests that elevations of VWF are not the sole driver of the prothrombotic state of APS and is consistent with the "multi-factorial" activation hypothesis of APS. In contrast to our supernatant experiments, we did not detect an increase in VWF release in the form of VWF-platelet strings F I G U R E 3 ADAMTS13 mediated VWF-platelet string cleavage is inhibited by Anti-β2GPI antibody APS155. HUVECs are seeded in a channel slide and are stimulated with 50 ng/mL PMA. After platelet perfusion, images are captured at standardized locations to represent the maximal formation of VWF-platelet strings. After capture, ADAMTS13 (standardized to 8% of PNP), in the presence of control or patient-derived Anti-β2GPI antibodies, is perfused and images are again captured at the identical standardized locations. Loss of platelets after perfusion is thus the quantitative measure of ADAMTS13 activity. Control experiments in the presence and absence of ADAMTS13 are shown in black bars on the far right. Outliers were removed using Graphpad 7 ROUT function with Q=1% from all conditions. N3 and statistical significance is analyzed with a one-way ANOVA with Holm-Sidak's multiple comparison test. Error bars represent the means SEM. Statistical significance is shown with capped lines (**P < .01, ****P < .0001) Using a FRET-based assay, platelet poor plasma was assayed for ADAMTS13 activity in patients from the same draw as used for isolation of anti-β2GPI antibodies. Results are shown in duplicate and a lab standard normal plasma as a standard control is also shown.
on endothelial cells in response to anti-β2GPI IgG. Although the presence of VWF-platelet strings has been noted upon exposure of endothelial cells to agonists such as PMA, histamine, some pro inflammatory cytokines, 35 and have been visualized in vivo, 36 the role of VWF-platelet string formation in APS needs further evaluation. 37 We also only investigated the formation at one shear rate, 5 dynes/ cm 2 and it is possible that a phenotype of increased VWF plateletstring formation would be revealed at higher or lower shear rates.
Our results are consistent with previous reports that demonstrated VWF release from endothelial cells in the presence of APLA. [31] [32] [33] However, all of these studies used either serum or a total
IgG fraction from patients with APS and here we specifically focused on the effects of anti-β2GPI antibodies derived from patients with APS to induce VWF release, as they have been shown to potentiate thrombosis in several in vivo models. 7, 9, 10 In contrast to previous reports, 24,26 β2GPI was not strictly required for VWF release in our studies. Although it has been suggested that β2GPI is necessary for targeting of anti-β2GPI antibodies, many of the previous studies specifically studying anti-β2GPI induced VWF release 31, 32 were conducted with unknown levels of β2GPI. We also sought to investigate the effect of anti-β2GPI antibodies on ADAMTS13 activity as ADAMTS13 dysfunction, which classically results in microvascular thrombi such as that seen in TTP, has been recently linked to thromboembolic events such as myocardial infarction, DVT, and stroke. [38] [39] [40] In addition to thromboembolic events ADAMTS13 may have effects on early miscarriage; there are reports of higher miscarriage rates in TTP although a recent report noted no significant changes in ADAMTS13 levels in those with recurrent miscarriages. 41, 42 We demonstrated that APS155 caused a mild decrease in ADAMTS13 activity by FRET assay and that anti-β2GPI
antibodies purified from that patient inhibited ADAMTS13's ability to cleave VWF-platelet strings. This VWF-platelet string model has been used previously to assess ADAMTS13 activity under conditions of shear stress which allows for the unraveling of VWF. 20, 43 We also observed an increase of the higher molecular weight multimers in APS samples, as previously reported by Austin et al. 21 We note that although decreased, the levels of ADAMTS13 in our samples were still within the normal range for ADAMTS13 activity, and thus anti-β2GPI antibodies alone were unable to fully inhibit ADAMTS13 activity at the concentrations tested. However, a recent publication demonstrated that mildly decreased ADAMTS13 activity levels were associated with acute and chronic cerebrovascular disease patients suggestive that even mild decrease may represent a prothrombotic risk factor. 40 These findings suggest that anti-β2GPI antibodies may F I G U R E 4 VWF Multimer Pattern from patients with APS. PPP from each APS patient was run on a VWF multimer gel to resolve multimer patterns via SDS agarose gel electrophoresis followed by western blotting. The same was standardized to 1 mU of total protein in each lane and the plasma sample loaded was the same draw as that used to isolated anti-β2GPI antibodies as well as run the FRET-based assay in Table 1 . Two lanes between APS203 and APS698 were excluded from analysis and removed from this image. Densitometry analysis of high molecular weight bands was performed. The black box in Figure 4A demonstrates the approximate area upon which analysis was conducted, analysis of the band intensity as measured by ImageJ/FIJI is demonstrated in 4B. have heterogenous effects on VWF release/ADAMTS13 activity. antibodies, such as binding to the A2 domain of VWF or the active site of ADAMTS13 due to cross-reactive epitopes needs to be further elucidated. The effects of different shear rates is also worthy of future study. 46 Global limitations of our study include a relatively small number of anti-β2GPI antibodies tested in our VWF models and a single concentration tested for efficacy. We were primarily limited by the total amount of anti-β2GPI antibodies available for all of our assays and thus chose to use a previously published concentration that demon- In summary, we demonstrated that some anti-β2GPI antibodies can induce VWF release from human endothelial cells and inhibit ADAMTS13 activity. These findings have important implications for the role that VWF may play in the prothrombotic phenotype of APS and suggest that targeting VWF may ameliorate the predisposition to thrombosis seen in this disease.
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